Equities Analysts Set Expectations for GALT FY2029 Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – HC Wainwright issued their FY2029 earnings per share estimates for Galectin Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst E. Arce expects that the company will earn ($0.91) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share.

Separately, StockNews.com downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

Galectin Therapeutics Price Performance

GALT stock opened at $1.32 on Friday. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. The business’s 50-day moving average is $1.46 and its two-hundred day moving average is $1.94. The firm has a market capitalization of $82.85 million, a P/E ratio of -1.81 and a beta of 0.69.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Monday, March 31st. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).

Institutional Trading of Galectin Therapeutics

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Galectin Therapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 870,589 shares of the company’s stock valued at $1,124,000 after buying an additional 8,047 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Galectin Therapeutics by 19.0% in the 4th quarter. Bank of New York Mellon Corp now owns 50,826 shares of the company’s stock valued at $66,000 after acquiring an additional 8,105 shares during the last quarter. Inspire Advisors LLC grew its holdings in Galectin Therapeutics by 86.3% in the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company’s stock valued at $27,000 after purchasing an additional 9,772 shares during the period. Northern Trust Corp increased its position in Galectin Therapeutics by 4.3% during the 4th quarter. Northern Trust Corp now owns 244,274 shares of the company’s stock worth $315,000 after purchasing an additional 9,994 shares in the last quarter. Finally, Stratos Wealth Partners LTD. increased its holdings in Galectin Therapeutics by 27.4% in the 4th quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company’s stock valued at $66,000 after purchasing an additional 11,100 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.